AXL and sarcoma: Table 3). The rationale for combining this ADC with nivolumab is intriguing, as AXL overexpression is associated with aggressive behavior and immune resistance in sarcomas. In fact, preliminary published results from the first part of the study revealed a PFS of 39.9% and a disease control rate of 41.1%, with 5 responding patients (114).